YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas

Miao Wang; Siyu Qian; Yue Zhang; Qingjiang Chen; Xudong Zhang; Mingzhi Zhang

doi:10.2174/0115680096328745250122231110

image of YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas

YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas
Authors: Miao Wang¹, Siyu Qian¹, Yue Zhang¹, Qingjiang Chen¹, Xudong Zhang¹ and Mingzhi Zhang¹
View Affiliations Hide Affiliations

¹ Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China
Source: Current Cancer Drug Targets
Available online: 17 March 2025
DOI: https://doi.org/10.2174/0115680096328745250122231110
- Received: 06 May 2024
- Accepted: 28 Oct 2024
- Available online: 17 Mar 2025

Abstract

Introduction

Yippee Like 1 (YPEL1) is a nuclear protein involved in various cellular processes, including cell cycle regulation, senescence, and mammalian development. It plays a dual role in cancer, functioning as either an antitumor or tumor-promoting factor.

Methods

We assessed the RNA and protein levels of YPEL1 in both NK/T-cell,lymphoma cell lines and gemcitabine-resistant lymphoma cells using qPCR and western blot, respectively. Flow cytometry was employed to analyze cellular apoptosis and the cell cycle. The impact of YPEL1 knockdown on the proliferation of NK/T-cell lymphoma cells was evaluated through CCK8 assay and a xenograft model, while transcriptomic analysis was conducted to explore the cellular signaling pathways influenced by YPEL1 silencing.

Results

In the current study, via The Cancer Genome Atlas (TCGA) search, we found that YPEL1 is aberrantly expressed in various cancers. High expression of YPEL1 correlated with poorer survival outcomes, whereas low expression of YPEL1 was associated with improved overall survival of patients. YT cell lines and gemcitabine-resistant YT cell line (YT/Gem-R) exhibit elevated levels of the YPEL1 protein

Conclusion

These findings suggest that YPEL1 exhibits the potential for being used as a target for NK / T cell lymphoma treatment.

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096328745250122231110

2025-03-17

2025-04-10

From This Site

/content/journals/ccdt/10.2174/0115680096328745250122231110

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

References

Hosono K. Sasaki T. Minoshima S. Shimizu N. Identification and characterization of a novel gene family YPEL in a wide spectrum of eukaryotic species. Gene 2004 340 1 31 43 10.1016/j.gene.2004.06.014 15556292
[Google Scholar]
Li W. Huang W. Wu K. Long Y. Yippee like 1 suppresses Glioma progression and serves as a novel prognostic factor. Tohoku J. Exp. Med. 2022 256 2 141 150 10.1620/tjem.256.141 35185081
[Google Scholar]
Truong L. Zheng Y.M. Song T. Tang Y. Wang Y.X. Potential important roles and signaling mechanisms of YPEL4 in pulmonary diseases. Clin. Transl. Med. 2018 7 1 e16 10.1186/s40169‑018‑0194‑5 29892964
[Google Scholar]
Oki K. Plonczynski M.W. Gomez-Sanchez E.P. Gomez-Sanchez C.E. YPEL4 modulates HAC15 adrenal cell proliferation and is associated with tumor diameter. Mol. Cell. Endocrinol. 2016 434 C 93 98 10.1016/j.mce.2016.06.022 27333825
[Google Scholar]
Berberich S.J. Todd A. Tuttle R. Why YPEL3 represents a novel tumor suppressor. Front. Biosci. 2011 16 1 1746 1751 10.2741/3817 21196260
[Google Scholar]
Zhang J Wen X Ren XY YPEL3 suppresses epithelial-mesenchymal transition and metastasis of nasopharyngeal carcinoma cells through the Wnt/β-catenin signaling pathway J Exp Clin Cancer Res 2016 35 1 109
[Google Scholar]
Zhou D. Tang W. Xu Y. Xu Y. Xu B. Fu S. Wang Y. Chen F. Chen Y. Han Y. Wang G. METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5. Mol. Oncol. 2021 15 8 2172 2184 10.1002/1878‑0261.12898 33411363
[Google Scholar]
Kelemen L.E. Wang X. Fredericksen Z.S. Pankratz V.S. Pharoah P.D.P. Ahmed S. Dunning A.M. Easton D.F. Vierkant R.A. Cerhan J.R. Goode E.L. Olson J.E. Couch F.J. Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009 18 6 1864 1868 10.1158/1055‑9965.EPI‑08‑0486 19454617
[Google Scholar]
Farlie P. Reid C. Wilcox S. Peeters J. Reed G. Newgreen D. Ypel1: A novel nuclear protein that induces an epithelial‐like morphology in fibroblasts. Genes Cells 2001 6 7 619 629 10.1046/j.1365‑2443.2001.00445.x 11473580
[Google Scholar]
Roxström-Lindquist K. Faye I. The Drosophila gene Yippee reveals a novel family of putative zinc binding proteins highly conserved among eukaryotes. Insect Mol. Biol. 2001 10 1 77 86 10.1046/j.1365‑2583.2001.00239.x 11240639
[Google Scholar]
Tan T.Y. Gordon C.T. Miller K.A. Amor D.J. Farlie P.G. YPEL1 overexpression in early avian craniofacial mesenchyme causes mandibular dysmorphogenesis by up‐regulating apoptosis. Dev. Dyn. 2015 244 8 1022 1030 10.1002/dvdy.24299 26061551
[Google Scholar]
Wu X. Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis. Gene 2018 643 74 82 10.1016/j.gene.2017.12.003 29221754
[Google Scholar]
Abiatari I. Kiladze M. Kerkadze V. Friess H. Kleeff J. Expression of YPEL1 in pancreatic cancer cell lines and tissues. Georgian Med. News 2009 175 60 62 19893129
[Google Scholar]
Juang Y.L. Li D.Y. Tseng Y.W. Yang C-H. Chang C-Y. LMO7 is a MAD1‐interacting protein and has a role in mitosis. FASEB J. 2013 27 S1 27 10.1096/fasebj.27.1_supplement.lb66
[Google Scholar]
Abiatari I. DeOliveira T. Kerkadze V. Schwager C. Esposito I. Giese N.A. Huber P. Bergman F. Abdollahi A. Friess H. Kleeff J. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol. Cancer Ther. 2009 8 6 1494 1504 10.1158/1535‑7163.MCT‑08‑0755 19509238
[Google Scholar]
Li S. Sun M.Y. Su X. MiR-885-5p promotes gastric cancer proliferation and invasion through regulating YPEL1. Eur. Rev. Med. Pharmacol. Sci. 2019 23 18 7913 7919 31599416
[Google Scholar]
Penrose H.M. Heller S. Cable C. Nakhoul H. Ungerleider N. Baddoo M. Pursell Z.F. Flemington E.K. Crawford S.E. Savkovic S.D. In colonic ρ0 (rho0) cells reduced mitochondrial function mediates transcriptomic alterations associated with cancer. Oncoscience 2017 4 11-12 189 198 10.18632/oncoscience.386 29344557
[Google Scholar]
Wang L. Zhang Z. Zhou X. Wu J. Hong Z. Comprehensive analysis of the expression and prognosis of YPEL family members in clear cell renal cell cancer. Oncol. Rep. 2022 48 1 134 10.3892/or.2022.8345 35674183
[Google Scholar]
Mini E. Nobili S. Caciagli B. Landini I. Mazzei T. Cellular pharmacology of gemcitabine. Ann. Oncol. 2006 17 Suppl. 5 v7 v12 10.1093/annonc/mdj941 16807468
[Google Scholar]